Volume 7, Number 6—December 2001
Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination
|Age (years)||No. doses||No. OAEa||OAE reports/100,000 doses||RRR (95% CI)||No. SyAEb||SyAE reports/ 100,000 doses||RRR (95% CI)|
|15-24||189,991||11||5.79||2.5 (1.2-5.5)||3||1.58||1.0 (0.3-3.6)|
|45-64||442,605||8||1.81||0.8 (0.3-1.9)||12||2.71||1.7 (0.8-3.9)|
|65-74||86,222||1||1.16||0.5 (0.1-3.8)||5||5.80||3.7 (1.3-10.7)|
CI = confidence intervals; Ref = reference.
aOAE: other adverse event (uncomplicated neurologic/systemic, hypersensitivity, or local reaction).
bSyAE: systemic adverse event (multisystemic [excluding anaphylactic] or neurologic reaction).
1Jeff Altman, University of Washington, Seattle, Washington; Vernon Ansdell, Kaiser Permanente, Honolulu, Hawaii; Elizabeth Barnett, Boston University, Boston, Massachusetts; Michele Barry Yale University, New Haven, Connecticut; Bradley Connor, Cornell University, New York, New York; David Freedman, University of Alabama at Birmingham, Birmingham, Alabama; Alejandra Gurtman, Mount Sinai Medical Center, New York, New York; Elaine Jong, University of Washington, Seattle, Washington; Phyllis Kozarsky, Emory University, Atlanta, Georgia; Russell McMullen, University of Washington, Seattle, Washington; Jan Patterson, University of Texas, San Antonio, Texas; Bradley Sack, Johns Hopkins University, Baltimore, Maryland; Mary E. Wilson, Harvard University, Cambridge, Massachusetts; Martin Wolfe, Traveler's Medical Service of Washington, Washington, D.C.
- Page created: December 09, 2010
- Page last updated: December 09, 2010
- Page last reviewed: December 09, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)